NEW YORK – The US Food and Drug Administration on Friday approved Syndax Pharmaceuticals' Revuforj (revumenib) as a treatment for adult and pediatric patients one year and older with relapsed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback